Catalyst

Slingshot members are tracking this event:

Valeant's (VRX) Bausch + Lomb Resubmits New Drug Application (NDA) for Latanoprostene Bunod Ophthalmic Solution for Lowering Intraocular Pressure in Patients with Open Angle Glaucoma or Ocular Hypertension

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
VRX

100%
Bausch + Lomb

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 27, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords New Drug Application, Resubmission, Fda, Latanoprostene Bunod, Ophthalmic Solution, Lowering Intraocular Pressure, Open Angle Glaucoma, Ocular Hypertension